Soleil Boughton Sells 4,153 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 4,153 shares of Hims & Hers Health stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $35.30, for a total value of $146,600.90. Following the sale, the insider now directly owns 161,497 shares of the company’s stock, valued at approximately $5,700,844.10. This trade represents a 2.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, January 21st, Soleil Boughton sold 54,153 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total value of $1,619,174.70.
• On Monday, January 6th, Soleil Boughton sold 268,932 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.75, for a total value of $7,462,863.00.
• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total value of $70,055.70.

Hims & Hers Health Stock Performance

Hims & Hers Health stock opened at $41.94 on Wednesday. The business’s 50-day simple moving average is $29.58 and its two-hundred day simple moving average is $22.86. The company has a market cap of $9.16 billion, a PE ratio of 95.32 and a beta of 1.35. Hims & Hers Health, Inc. has a fifty-two week low of $8.51 and a fifty-two week high of $41.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.04) EPS. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HIMS. Piper Sandler lifted their price target on Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Deutsche Bank Aktiengesellschaft lifted their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Bank of America downgraded Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price target for the company from $32.00 to $18.00 in a report on Thursday, November 14th. BTIG Research began coverage on Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, Needham & Company LLC lifted their price target on Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 6th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $25.13.

Institutional Trading of Hims & Hers Health

Several large investors have recently added to or reduced their stakes in HIMS. Crewe Advisors LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. lifted its holdings in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after buying an additional 1,100 shares during the period. Venturi Wealth Management LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at about $48,000. GAMMA Investing LLC lifted its holdings in shares of Hims & Hers Health by 2,173.7% in the 4th quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock valued at $54,000 after buying an additional 2,152 shares during the period. Finally, Principal Securities Inc. lifted its holdings in shares of Hims & Hers Health by 48.2% in the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after buying an additional 1,002 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.